Search

Objective: The purpose of the present study was to evaluate the efficacy and tolerability of olanzapine long-acting injection for maintenance treatment of schizophren ia. Method: Outpatients with schizophrenia who had maintained stability on an oral regimen of olanzapine (10, 15, or 20 mgI day) for 4 to 8 weeks were randomly assigned to 24 weeks of double-blind treatment with "low" (150 mg every 2 weeks; N=140),"medium"(4O5mgevery4weeks; N=318), or "high" (300 mg every 2 weeks; N=141) doses of olanzapine long-acting injection; a very low reference dose of olanzapine long-acting injection (45 mg every 4 weeks; N=144); or their stabilized dose of oral olanzapine (N=322). Rates of and time to psychotic exacerbation were estimated using Kaplan-Meier methodology. Results: At 24 weeks, the majority of oral olanzapine-treated patients (93%), as well as most olanzapine long-acting injectiontreated patients receiving high (95%), medium (90%), low (84%), and very low doses (69%), remained exacerbation free, with the therapeutic 4-week regimen (medium dose) and pooled 2-week regimen (low and high doses) demonstrating efficacy similar to that of oral olanzapine as well as to each other. The three standard long-acting doses were superior to the very low reference dose based on time to exacerbation. Incidence of weight gain ⩾7% of baseline was 21% for oral olanzapine compared with 21%, 15%, 16%, and 8% for the high, medium, low, and very low olanzapine long-acting treatment groups, respectively. No clinically significant differences were observed between the long-acting injection and oral olanzapine groups in general safety parameters. Few injection-site reactions occurred (3%). Two patients experienced sedation and delirium consistent with olanzapine overdose following possible accidental intravascular injection. Conclusions: Olanzapine long-acting injection was efficacious in maintenance treatment of schizophrenia for up to 24 weeks, with a safety profile similar to oral olanzapine except for injection-related adverse events. [ABSTRACT FROM AUTHOR]

Evaluates the neurohormonal and subjective mood response of children with anxiety disorders who were challenged with yohimbine. Uniform well tolerance to yohimbine in, and behavioral differences between, children with anxiety disorders and normal comparison children; Presence of a blunted growth hormone response to yohimbine in children with anxiety disorders.